Concert Looks To Phase III In Alopecia Areata, Ahead Of Pfizer’s JAK Inhibitor

 
• By Joseph Haas

Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.

Desperate Young Man Touching His Bald Patches - Image
Concert hopes to bring the first drug therapy for alopecia areata to market

More from Clinical Trials

More from R&D